Compare Danaher Corporation (DHR) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Prudential PLC — how do they compare? Danaher Corporation trades at $206.83 (market cap $145.83B), while Prudential PLC trades at $27.5 (market cap $34.02B). The key difference: Danaher Corporation is far larger — about 4.3× Prudential PLC's market cap, and Prudential PLC pays the higher dividend (1.94%). Which is the better fit depends on your goals.
| DHR | PUK | |
|---|---|---|
Market Cap | $145.83B | $34.02B |
Sector | Health | Financials |
52-Week High | $242.05 | $33.61 |
52-Week Low | $161.91 | $24.98 |
Enterprise Value | $168.04B | $35.46B |
Dividend Yield | 0.77% | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Prudential PLC (PUK) trades at $27.48, down 2.62% today, with a bearish technical signal but strong fundamentals including a P/E of 8.92, net income margin of 14.52%, and recent earnings beats. Revenue grew to $16.21B in 2024, with net income of $2.29B, while cash flow from operations surged to $3.61B. Recent news highlights a dividend declaration and strategic acquisitions, but shares face pressure from China regulatory concerns.
The outlook is mixed: attractive valuation and profitability support upside, but bearish technicals and China-related risks pose headwinds. Analyst consensus leans buy (50%), with institutional focus on execution of cost-cutting and geographic strategy. Key risks include regulatory changes in Asia and market volatility impacting near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
